These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 26964658)

  • 1. The role of the 'central' cholecystokinin-B receptor in panic disorder.
    Megen HJ; Westenberg HG; Boer JA
    Acta Neuropsychiatr; 1996 Dec; 8(4):99-101. PubMed ID: 26964658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin.
    Zwanzger P; Domschke K; Bradwejn J
    Depress Anxiety; 2012 Sep; 29(9):762-74. PubMed ID: 22553078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin in anxiety.
    van Megen HJ; Westenberg HG; den Boer JA; Kahn RS
    Eur Neuropsychopharmacol; 1996 Nov; 6(4):263-80. PubMed ID: 8985709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin and panic disorder: past and future clinical research strategies.
    Bradwejn J; Koszycki D
    Scand J Clin Lab Invest Suppl; 2001; 234():19-27. PubMed ID: 11713976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety.
    Hernandez-Gómez AM; Aguilar-Roblero R; Pérez de la Mora M
    Amino Acids; 2002; 23(1-3):283-90. PubMed ID: 12373548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.
    van Megen HJ; Westenberg HG; den Boer JA; Slaap B; Scheepmakers A
    Psychopharmacology (Berl); 1997 Feb; 129(4):357-64. PubMed ID: 9085405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
    McCann UD; Slate SO; Geraci M; Uhde TW
    Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers.
    Zwanzger P; Eser D; Padberg F; Baghai TC; Schule C; Rötzer F; Ella R; Möller HJ; Rupprecht R
    Depress Anxiety; 2003; 18(3):140-3. PubMed ID: 14625878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic and intra-dorsal periaqueductal gray injections of cholecystokinin sulfated octapeptide (CCK-8s) induce a panic-like response in rats submitted to the elevated T-maze.
    Zanoveli JM; Netto CF; Guimarães FS; Zangrossi H
    Peptides; 2004 Nov; 25(11):1935-41. PubMed ID: 15501525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies.
    Harro J
    Amino Acids; 2006 Oct; 31(3):215-30. PubMed ID: 16738800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
    Zwanzger P; Baghai TC; Schuele C; Ströhle A; Padberg F; Kathmann N; Schwarz M; Möller HJ; Rupprecht R
    Neuropsychopharmacology; 2001 Nov; 25(5):699-703. PubMed ID: 11682253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cholecystokinin hypothesis of panic and anxiety disorders: a review.
    Bradwejn J; Koszycki D; du Tertre AC; Bourin M; Palmour R; Ervin F
    J Psychopharmacol; 1992 Jan; 6(3):345-51. PubMed ID: 22291378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels.
    Radu D; Ahlin A; Svanborg P; Lindefors N
    Psychopharmacology (Berl); 2002 Jun; 161(4):396-403. PubMed ID: 12073167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the significance of cholecystokinin receptors in panic disorder.
    van Megen HJ; den Boer JA; Westenberg HG
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1235-46. PubMed ID: 7863014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder.
    van Megen HJ; Westenberg HG; Den Boer JA; Kahn RS
    Eur Neuropsychopharmacol; 1996 Aug; 6(3):187-94. PubMed ID: 8880078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.
    Zwanzger P; Rupprecht R
    J Psychiatry Neurosci; 2005 May; 30(3):167-75. PubMed ID: 15944741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurobiological investigations into the role of cholecystokinin in panic disorder.
    Bradwejn J
    J Psychiatry Neurosci; 1993 Jul; 18(4):178-88. PubMed ID: 8104032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects.
    Ströhle A; Graetz B; Scheel M; Wittmann A; Feller C; Heinz A; Dimeo F
    J Psychiatr Res; 2009 Aug; 43(12):1013-7. PubMed ID: 19289240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of induced effects by selective CCKB agonists cholecystokinin in the nociception and behavior in rodents].
    Dauge V; Derrien M; Durieux C; Noble F; Corringer PJ; Roques BP
    Therapie; 1992 Nov; 47(6):531-9. PubMed ID: 1301645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
    Ströhle A; Holsboer F; Rupprecht R
    Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.